Pernix Therapeutics Holdings, a specialty pharmaceutical company, has completed the acquisition of Cypress Pharmaceuticals, Inc., a privately owned generic pharmaceutical company, and Hawthorn Pharmaceuticals, Inc., a privately owned branded pharmaceutical company. Under the terms of the definitive agreement announced on November 14, 2012 and as amended on December 28, 2012, Pernix will pay up to $102 million, including an up-front payment of $52.0 million in cash and $34.0 million in equity (approximately 4.4 million shares of the company’s common stock) at closing as well as up to $11 million payable in December 2013 and an additional $5 million in a milestone payment.

In connection with the closing of the acquisition, the Pernix completed a $42 million credit facility. MidCap Financial served as sole bookrunner, administrative agent and co-lead arranger. Cypress and Hawthorn significantly increases and broadens the company’s branded and generic product portfolio.

Cooper Collins, president and CEO of Pernix, said, “We are pleased to close on this transaction before the end of the year. We believe the acquisition of Cypress and Hawthorn are an excellent fit for Pernix, and will serve as a key driver for the company’s future growth. We plan to rapidly integrate the branded business of Hawthorn and the generic business of Cypress, and we expect to capitalize on the synergies of the combined companies.”

Pernix Therapeutics is a specialty pharmaceutical company primarily focused on the sales, marketing, manufacturing and development of branded, generic and OTC pharmaceutical products. The Company manages a portfolio of branded and generic products.